Breaking News, Collaborations & Alliances

Boehringer, Hanmi, in Exclusive Next-Gen EGFR Alliance

To develop HM61713 as a targeted therapy for lung cancer

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Boehringer Ingelheim and Hanmi Pharmaceutical Co. entered an exclusive license and collaboration agreement for the development and commercialization of HM61713, a next-gen EGFR targeted therapy for the treatment lung cancer. HM61713 is currently in Phase II development in patients with non-small cell lung cancer (NSCLC) with T790M mutations who have developed resistance to previous EGFR targeting agents. A Phase III program will be initiated in 2016.   Hanmi will receive an initial payment of ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters